Tekmira Pharmaceuticals Corporation Doses First Subject In Human Clinical Trial Of TKM-Ebola

VANCOUVER, British Columbia, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has dosed the first subject in a Phase I human clinical trial of TKM-Ebola, an anti-Ebola viral therapeutic that is being developed under a US$140 million contract with the U.S. Department of Defense.

Help employers find you! Check out all the jobs and post your resume.